<DOC>
	<DOCNO>NCT01944306</DOCNO>
	<brief_summary>Contraceptive failure primary cause unintended pregnancy United States . With obesity rate epidemic proportion , association obesity strategy prevent undesired pregnancy constitute significant public health economic concern . Evidence recent epidemiological study preliminary data ( sub-therapeutic level steroid hormone due drug clearance half-life ) suggest obesity reduces oral contraceptive efficacy . Furthermore , preliminary analysis suggest sub-group obese woman , define birth weight , high risk contraceptive failure . Further study necessary investigate whether birth weight , surrogate marker utero growth restriction , useful diagnostic marker identification woman prone contraceptive failure . Such understanding critical finding contraceptive strategy well efficacy woman . The overall goal project test pharmacokinetics oral contraceptive agent obese woman low birth weight compare obese woman normal birth weight . The main hypothesis proposal adverse utero environment program expression function enzymes transporter underlie pharmacokinetics oral contraceptive , lead contraceptive failure . Reproductive-aged , ovulatory woman obese BMI &gt; 30 kg/m2 normal birth weight ( 5.5-8 lb ; n=10 ) low birth weight ( &lt; 5.5 lb ; n=10 ) , place oral contraceptive 1 month . At several key time point , synthetic steroid pharmacokinetics , gonadotropin ( luteinizing hormone , follicle-stimulating hormone ) ovarian hormone level ( estradiol , progesterone ) monitor .</brief_summary>
	<brief_title>Obesity Oral Contraceptive Failure</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Fetal Growth Retardation</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>age 18 35. single progesterone level 3 ng/mL great luteal phase ( day 18 25 ) menstrual cycle prior dose oral contraceptive . absolute/relative contraindication ethinyl estradiol levonorgestrel . impaired liver function . history deep venous thrombosis . hypertension ( &gt; 140/90 ) . diabetes vascular change . migraine aura neurological change . history myocardial infarction , pulmonary embolus , stroke breast cancer . anemia ( hematocrit &lt; 36 % ) . actively seek involved weight loss program ( must weight stable ) pregnancy , breastfeeding , seek pregnancy . diagnosis Polycystic Ovarian Syndrome . recent ( 4 week ) use hormonal contraceptive ( patch ring include ) , intrauterine , implantable hormonal contraception . DepoProvera use within six month . current use drug interfere metabolism sex steroid . smoker . uncontrolled thyroid dysfunction .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacology , Clinical</keyword>
	<keyword>Drug Efficacy</keyword>
	<keyword>Drug Failure</keyword>
	<keyword>Contraceptive Agents</keyword>
</DOC>